Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | TNKS | O95271 | 2/20 | 0.44 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124127 | 0.87 | KMT2A (0.52) | TNKS2PKMKMT2AMEN1TNKS | |
| SCHEMBL11286970 | 0.84 | TNKS2 (0.58) | TNKS2PKMKMT2AMEN1ALDH1A1 | |
| SCHEMBL6124115 | 0.81 | TNKS2 (0.72) | TNKS2KMT2AMEN1TNKSPARP3 | |
| SCHEMBL6124128 | 0.79 | HTR1A (0.44) | KMT2AMEN1MAPTCYP19A1SMN1; SMN2 | |
| SCHEMBL28837986 | 0.79 | TNKS2 (0.66) | TNKS2PKMKMT2AMEN1TNKS | |
| SCHEMBL5277109 | 0.74 | CA12 (0.53) | PKMKMT2AMEN1ALDH1A1MAPT | |
| Ammonia Solution, Strong SCHEMBL7244192 | 0.72 | CA12 (0.51) | PKMKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL12591983 | 0.72 | MEN1 (0.52) | TNKS2PKMKMT2AMEN1ALDH1A1 | |
| SCHEMBL4259970 | 0.72 | KDM4E (0.48) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19386770 | 0.72 | CASP3 (0.57) | KMT2AMEN1ALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133136-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133136-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-8642610-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642610-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-8178545-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | TP53, MAP2, MAP1LC3B | TNKS2 476/4885PKM 3984/4885KMT2A 2368/4885 |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | TP53, MAP2, MAP1LC3B | TNKS2 476/4885PKM 3984/4885KMT2A 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.